Compare
Jyong Biotech Ltd. vs Abvc Biopharma, Inc. vs Annovis Bio, Inc. vs Nexentis Technologies Inc.
| Latest fiscal year | Jyong Biotech Ltd. MENS | Abvc Biopharma, Inc. ABVC | Annovis Bio, Inc. ANVS | Nexentis Technologies Inc. NXTS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $296.0K | $0 | n/a |
| Revenue growth (YoY) | n/a | -41.9% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$4.67M | -$7.91M | -$28.85M | -$4.00M |
| EPS (Diluted) | -$0.06 | -$0.39 | -$1.40 | -$8.61 |
| Operating cash flow | -$3.04M | -$2.99M | -$25.62M | -$3.81M |
| Free cash flow | n/a | n/a | n/a | -$3.82M |
| Cash & equivalents | n/a | $681.5K | $19.53M | $3.83M |
| Total assets | $20.78M | $21.06M | $21.08M | $20.41M |
| Total liabilities | $45.68M | $7.76M | $4.23M | $4.67M |
| Shareholders' equity | -$24.91M | $11.11M | $16.85M | $16.01M |
| Return on year-end equity | n/a | -71.2% | -171.2% | -25.0% |
| Shares outstanding | 76.03M | 25.05M | 27.20M | 2.77M |
Revenue, most recent five fiscal years
| Fiscal year | Jyong Biotech Ltd. | Abvc Biopharma, Inc. | Annovis Bio, Inc. | Nexentis Technologies Inc. |
|---|---|---|---|---|
| Latest | n/a | $296.0K Ended 2025-12-31 | $0 Ended 2025-12-31 | $210.0K Ended 2024-12-31 |
| 1 year earlier | n/a | $509.6K Ended 2024-12-31 | $0 Ended 2024-12-31 | $263.0K Ended 2023-12-31 |
| 2 years earlier | n/a | n/a | $0 Ended 2023-12-31 | $394.0K Ended 2022-12-31 |
| 3 years earlier | n/a | n/a | $0 Ended 2022-12-31 | $438.1K Ended 2021-12-31 |
| 4 years earlier | n/a | n/a | $0 Ended 2021-12-31 | $232.3K Ended 2020-12-31 |